Faloppi, Luca <br/><br/>
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.  [electronic resource] 

 -  Oncotarget  Oct 2015 
 - 35087-94 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.5197  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Biomarkers, Tumor--blood<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>L-Lactate Dehydrogenase--blood<br/>Male<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>Pancreatic Neoplasms--blood<br/>Phenylurea Compounds--therapeutic use<br/>Prognosis<br/>Sorafenib